BioCentury | Aug 17, 2018
Clinical News

Eisai's Belviq does not increase MACE in CVOT for weight management drug

...an adjunct to diet and exercise for chronic weight management. Eisai has rights to the serotonin (5-HT2C) receptor...
...Diego, Calif. Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Product: Belviq lorcaserin Business: Endocrine/Metabolic Molecular target: Serotonin (5-HT2C) receptor...
...any coronary revascularization Status: Phase IIIb/IV data Milestone: NA Jennie Walters Belviq, lorcaserin (APD356) Arena Pharmaceuticals Inc. Eisai Co. Ltd. Serotonin (5-HT2C) receptor...
BioCentury | Aug 3, 2018
Company News

Eisai grants CY Biotech Greater China rights to lorcaserin

...will supply lorcaserin to CY Biotech. CY Biotech launched lorcaserin in Taiwan last year. The serotonin (5-HT2C) receptor...
BioCentury | May 1, 2018
Distillery Therapeutics

Neurology

...compound for obesity along with CY Biotech Co. Ltd. and Teva Pharmaceutical Industries Ltd. TARGET/MARKER/PATHWAY: Serotonin (5-HT2C) receptor...
...email: jizhou@utmb.edu CONTACT: Kathryn Cunningham, same affiliation as above email: kcunning@utmb.edu Chris Lieu University of Texas Medical Branch Serotonin (5-HT2C) receptor Addiction...
BioCentury | Sep 21, 2017
Targets & Mechanisms

Appetite for GFRAL

Simultaneous publications from Eli Lilly and Co ., Johnson & Johnson and Novo Nordisk A/S identifying GFRAL as the receptor of the anti-obesity hormone GDF15 will undoubtedly accelerate therapeutic translation of the pathway. The race...
BioCentury | Jul 21, 2017
Clinical News

Phase III CAMELLIA-TIMI CVOT for Belviq ongoing

...Calif. Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Product: Belviq lorcaserin (APD356) Business: Endocrine/Metabolic Molecular target: Serotonin (5-HT2C) receptor...
...II diabetes Status: Phase IIIb/IV ongoing Milestone: Complete Phase IIIb/IV (2018) Alicia Parker Belviq lorcaserin Arena Pharmaceuticals Inc. Eisai Co. Ltd. Serotonin (5-HT2C) receptor...
BioCentury | Jun 1, 2017
Politics & Policy

NIH seeks public-private partnerships to fight opioid crisis

...targeting kappa opioid receptor ( KOR ; OPRK1), neurokinin 1 receptor ( NK1R ; TACR1), serotonin (5-HT2C) receptor...
...receptor (KOR) (OPRK1) Mu opioid receptor (MOR) (OPRM1) Nav1.7 (SCN9A) Neurokinin 1 (NK1) substance P receptor (TACR1) Serotonin (5-HT1A) receptor Serotonin (5-HT2C) receptor Tumor...
BioCentury | Apr 7, 2017
Strategy

Pushing for progress in Prader-Willi

...nucleolar RNA (SNORD116) Small nucleolar RNA (snoRNA) Gene loss causes growth deficiency, anxiety and hyperphagia Serotonin (5-HT2C) receptor...
BioCentury | Mar 16, 2017
Targets & Mechanisms

Bone appétit!

Last week’s Nature publication of a hormone secreted by bone that suppresses appetite and can curb weight gain not only adds to the emerging picture of bone as a player in the endocrine system but...
BioCentury | Jan 6, 2017
Company News

Arena, Eisai deal

...to Ildong, Israeli rights to Abic and Taiwanese rights to CY Biotech. Belviq is a serotonin (5-HT2C) receptor...
...San Diego, Calif. Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Business: Endocrine/Metabolic Chris Lieu Belviq Arena Pharmaceuticals Inc. Eisai Co. Ltd. Serotonin (5-HT2C) receptor...
BioCentury | Jan 5, 2017
Company News

Arena sells off Belviq rights

...sales as physicians have hesitated to wade into the obesity treatment milieu. Belviq is a serotonin (5-HT2C) receptor...
...on Wednesday. It gained $0.03 to $1.50 during regular trading hours. Becky Simon Belviq Arena Pharmaceuticals Inc. Eisai Co. Ltd. Serotonin (5-HT2C) receptor Obesity...
Items per page:
1 - 10 of 280